Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cipla Resets Biosimilars Interest, Readies Respiratory-Focused JV

Executive Summary

Cipla moves beyond in-licensing approach and teams up with CDMO Kemwell to develop and progress respiratory biosimilars. Commercialization of products anticipated post 2025.

You may also be interested in...



Cipla Targets Global Respiratory Biosimilars With Kemwell JV

Cipla is to establish a new company with CDMO Kemwell Biopharma to develop and launch biosimilars for the global market, especially in the respiratory space, where Cipla has built a considerable presence for inhalation products.

How Cipla Is Shaping Lung Leadership Beyond Asthma, AMR Plans

CEO Umang Vohra outlines where Cipla is heading in its priority areas of lung route therapies and antimicrobial resistance. He also weighs in on the simmering issue of intellectual property waivers for COVID-19 vaccines.

Sun Wants To Join The Biosimilars Party, In Time

India's Sun Pharma is to foray into biosimilars, targeting first approval status for “third wave” products. It trails several peers and the changed stance comes as biosimilars gain traction in markets including the US, where experts have predicted a “coming out party” in the next few years.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144962

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel